LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience today announced the expansion of the company’s leadership team with the addition of Erin R. McQuade, J.D., as general counsel and chief administrative officer (CAO). Ms. McQuade brings decades of experience in advising public and private companies, including life science companies, to support Alto’s legal and human resources functions.
“Erin has a strong track record of governing life science companies through multiple stages of growth which will be a tremendous value driver as we expand our human resources department in parallel with ongoing clinical trials and scientific research,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. “Her expertise in legal strategy overseeing patent portfolios, intellectual property licenses, and clinical trial agreements, will be key to supporting Alto as we continue to advance novel medicines and execute on our mission to help patients get better faster.”
Ms. McQuade added, “I am eager to get to work with Alto’s dedicated team at such an important time in development and looking forward to building on recent momentum to further position Alto as a leader in precision psychiatry. As the company continues to mature, I look forward to leveraging my background in corporate governance and strategy to guide Alto’s legal and human resources functions.”
Ms. McQuade is an experienced advisor with over 20 years of leadership focused on securities law, corporate governance, executive compensation, M&A and finance. Prior to joining Alto, she served as vice president, legal at Levo Therapeutics, Inc. where she was responsible for advising on all legal matters including IP protections, risk management, and corporate compliance. Previously, she was the deputy general counsel at Assertio Therapeutics, Inc., assistant general counsel and assistant secretary at Mead Johnson Nutrition Company, senior corporate counsel at Hyatt Hotels Corporation and vice president, associate general counsel at SPSS Inc. Ms. McQuade began her career at Latham & Watkins LLP. She earned her juris doctor from Georgetown University Law Center and bachelor’s degree from Duke University.
About Alto Neuroscience
Alto Neuroscience is pioneering precision psychiatry by developing targeted medicines to help patients get better faster. Differences in individuals’ biology impact how they respond to treatment. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, behavioral task performance, wearable data, genetics, and other factors to match each patient with the right Alto drug. The company’s work in identifying and categorizing core domains of mental function (cognition, emotion, and sleep processes) has resulted in a multiple modality approach that supports robust drug-response predictions. Alto’s clinical-stage pipeline includes first- or best-in-class novel drug candidates in depression, PTSD, and other mental health conditions, resulting in the broadest and most-advanced precision psychiatry effort. For more information, visit https://www.altoneuroscience.com or follow us on Twitter.